US20190240166A1 - Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride - Google Patents
Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride Download PDFInfo
- Publication number
- US20190240166A1 US20190240166A1 US16/388,364 US201916388364A US2019240166A1 US 20190240166 A1 US20190240166 A1 US 20190240166A1 US 201916388364 A US201916388364 A US 201916388364A US 2019240166 A1 US2019240166 A1 US 2019240166A1
- Authority
- US
- United States
- Prior art keywords
- weight
- transdermal therapeutic
- therapeutic system
- acid hydrochloride
- aminolevulinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a transdermal therapeutic system and a transdermal active ingredient-containing plaster for 5-aminolevulinic acid hydrochloride. It also relates to the use of a system of this type in photodynamic diagnostics and therapy.
- Transdermal therapeutic systems have become widespread nowadays as a form of administration for treating numerous diseases, as they demonstrate certain advantages compared to conventional forms of administration.
- transdermal therapeutic systems can increase the therapeutic value of an active ingredient as they ensure a constant dispensing thereof.
- the advantages of transdermal therapeutic systems are also that, in comparison to ointments or creams, they can be applied to the precise area and therefore at the precise dosage. Furthermore, there is no danger of inadvertently wiping off the ointment and contaminating other locations on the skin.
- a transdermal therapeutic system for releasing 5-aminolevulinic acid is known from EP 1 467 706 A1.
- 5-aminolevulinic acid is selectively absorbed and enriched by tumor tissue, so it only leads to an increased porphyrin formation and concentration there, while the healthy tissue remains substantially uninfluenced.
- the effect of the 5-aminolevulinic acid is based on the stimulation of the body's own porphyrin formation.
- the 5-aminolevulinic acid or porphyrin enrichment can be used in diseased tissue to diagnose precancerous and cancerous lesions and for the protodynamic therapy thereof.
- EP 1 303 267 A1 The two systems have the drawback that the 5-aminolevulinic acid permeates through human skin only comparatively poorly.
- Actinic keratosis is designated an early form of white skin cancer, as the latter in 10% of cases can develop within a period of 10 years into a squamous cell carcinoma of the skin (spinalioma). It is chronic damage to the horny epidermis caused by the intensive action of sunlight (UV radiation) over many years.
- An important treatment method for actinic keratosis is so-called photodynamic therapy.
- An active ingredient is firstly applied here to the affected skin region and specific light-sensitive substances, the so-called porphyrins, increasingly form in the diseased skin cells. As a result, the cells are sensitised to the subsequent treatment with light and reactive oxygen is produced (photodynamic effect), which ultimately leads to the death of the corresponding cells.
- photodynamic therapy can furthermore be repeated virtually as often as desired if the actinic keratosis occurs again.
- photodynamic therapy also offers a diagnostic use. Using special light, the regions affected by actinic keratosis and pretreated by corresponding substances can be made visible in a targeted manner. It is thus possible to recognise the actinic keratosis early and to precisely determine the size of the locations affected (photodynamic diagnostics).
- the aim of the present invention is to provide a transdermal therapeutic system, which as quickly as possible releases an adequate quantity of a substance into precancerous and cancerous lesions in order to then carry out the photodynamic therapy by means of irradiation.
- the transdermal therapeutic system should be well tolerated by the skin, be flexible and adequately sticky, even on regions that are less well accessible, such as the nasal bone or the outer ear. Furthermore, the transdermal therapeutic system should be stable, visually unobtrusive, easy to apply and remove again.
- transdermal therapeutic system or a transdermal active ingredient-containing plaster, which comprises a back layer that is impermeable to an active ingredient, an active ingredient-containing polymer matrix and a protective layer that can be pulled off, and characterised in that 5-aminolevulinic acid hydrochloride is used as the active ingredient and in that the basic polymer of the polymer matrix is an adhesive polyacrylate.
- FIG. 1 graphically illustrates the released quantity of 5-ALA [mg/patch] versus time [h] for several exemplary embodiments.
- the transdermal therapeutic system according to the invention with 5-aminolevulinic acid hydrochloride as the active ingredient and an adhesive polyacrylate as the basic polymer of the polymer matrix is in a position to absorb adequately large quantities of the suspended pharmaceutical agent, i.e. of the 5-aminolevulinic acid hydrochloride.
- an adhesive polyacrylate as the basic polymer of the polymer matrix.
- the release rate of the 5-aminolevulinic acid hydrochloride during the application period is extraordinarily high.
- the transdermal therapeutic system according to the invention adheres adequately to the skin but does not irritate it
- the transdermal therapeutic system according to the invention can easily be applied, especially also to small skin regions, such as the forehead, the outer ear or the nose.
- the transdermal therapeutic system according to the invention is characterised in that it is capable, within about four hours, preferably within about an hour and especially preferably within about thirty minutes, of releasing a quantity of at least 3 mg 5-aminolevulinic acid hydrochloride (measured as 5-aminolevulinic acid with the so-called “paddle over disc” method, as described in European Pharmacopoeia 6.0, 2.9A “dissolution test for transdermal patches”, January 2008: 20904; see also Example 4).
- the transdermal therapeutic system according to the invention is preferably a monolithic active ingredient-in-adhesive system (monolithic drug-in-adhesive system).
- 5-aminolevulinic acid hydrochloride is suspended or dispersed directly in the polymer matrix here.
- the polymer matrix carries out the three functions of the active ingredient reservoir, the control element and the adhesive layer in this case.
- a system of this type consists only of a back layer that is impermeable to an active ingredient, an active ingredient-containing polymer matrix and a protective layer that can be pulled off.
- the polymer matrix influences the adhesion to the skin, the storage of the 5-aminolevulinic acid hydrochloride and its release.
- a system of this type leads to a plurality of advantages during the release of hydrophilic substances, such as 5-aminolevulinic acid hydrochloride.
- hydrophilic substances such as 5-aminolevulinic acid hydrochloride.
- further hydrophilic matrix materials can be avoided, so the microbiological stability is improved.
- the stability of the active ingredient is also increased as it is chemically inactivated. It is furthermore possible to control the release of the active ingredient by means of the particle size.
- the back layer that is impermeable to the active ingredient is preferably inert and as flexible as possible, so the transdermal therapeutic system can also be applied to irregular skin regions.
- Any suitable material such as, for example, polyethylene terephthalate, polyethylene, polybutylene, polyurethane, polyester, etc., can be used for the back layer.
- the back layer that is impermeable to an active ingredient is preferably an optionally aluminised polyester film, especially preferably a laminate made of pigmented polyethylene with aluminium vapour-coated polyester, which (provide) protection against light irradiation and therefore prevent photosensitisation before the actual photodynamic therapy.
- the protective layer that can be pulled off can be produced from various materials, such as, for example, polyethylene terephthalate, polyethylene or polypropylene and is specially treated on the side in contact with the active ingredient-containing polymer matrix in order to make it as easy as possible to remove therefrom.
- the protective layer that can be pulled off is advantageously based on a polyethylene terephthalate layer.
- the active ingredient 5-aminolevulinic acid hydrochloride is present as a crystalline 5-aminolevulinic acid hydrochloride. This has the advantage that the solubility of the active ingredient in the matrix does not have to be adjusted. Furthermore, an over-saturation and a constant diffusion pressure are thereby achieved.
- the active ingredient projects, so to speak, from the matrix, which has the advantage that on contact with the skin, especially with sweat, the projecting crystals very quickly dissolve and can therefore be easily and quickly transdermally absorbed.
- More than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are preferably smaller than about 250 ⁇ m. Although as the crystal size becomes larger, the epidermal flow increases, crystals that are too large, i.e. crystal sizes above about 250 ⁇ m, lead to clumping and streak formation.
- the quantity of crystals which are smaller than 90 ⁇ m, to make up at most 50%, and the quantity of crystals, which are smaller than 50 ⁇ m, to make up at most 25%, of the active ingredient mass, as this ensures a high active ingredient flow.
- a transdermal therapeutic system with 5-aminolevulinic acid hydrochloride crystals of a particle size of 90 to 160 ⁇ m exhibits a clearly improved transepidermal flow compared with a system with particles having a particle size of less than 90 ⁇ m. This is probably because more active ingredient is released and is therefore available for the permeation. Particle sizes in the range from 90 to 160 ⁇ m are therefore especially preferred.
- the polymer matrix of the transdermal therapeutic system according to the invention preferably contains less than 30% by weight, preferably less than 20% by weight and especially preferably less than 5% by weight of plasticiser, for example citric acid esters, such as acetyl tributyl citrate, in relation to polyacrylate.
- plasticiser for example citric acid esters, such as acetyl tributyl citrate.
- the plasticiser content in the transdermal therapeutic system according to the invention is quite especially preferably below 5000 ppm.
- So-called enhancers or permeation promoters can also preferably be dispensed with.
- the adhesive polyacrylate can be obtained with and advantageously without cross-linking agents (cross-linkers), such as, for example, aluminium acetylacetonate, polybutyl titanate or t-amyl peroxy pyrolate, etc.
- cross-linkers such as, for example, aluminium acetylacetonate, polybutyl titanate or t-amyl peroxy pyrolate, etc.
- the adhesive polyacrylate preferably has acid functionalities (carboxyl groups), as they are advantageous in relation to the adhesion. These are especially important when the crystals of the crystalline 5-aminolevulinic acid hydrochloride are larger than the layer thickness of the polymer matrix as whole-area contact between the transdermal therapeutic system and the skin is not then ensured.
- the adhesive polyacrylate with acid functionalities can, for example, be obtained by polymerisation of a monomer mixture containing an unsaturated carboxylic acid, such as, for example, acrylic acid, methacrylic acid or maleic acid.
- the monomer mixtures used to produce the adhesive polyacrylates can also contain acrylic acid derivatives with epoxy groups, such as, for example, glycidyl (meth)acrylate.
- the polyacrylate is preferably based on acrylic esters, such as, for example, 2-ethylhexyl acrylate. This is preferably used in a quantity of more than 50% by weight, especially more than 60% by weight and especially preferably in a quantity of more than 70% by weight, based on polyacrylate.
- the viscosity of the polyacrylate is preferably in the range from 500 to 25,000, especially preferably in the range from 1,000 to 20,000 and quite especially preferably in the range from 1,500 to 12,000 mPa ⁇ s at 25° C.
- the adhesive polyacrylate is polyacrylate based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and vinyl acetate, based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate, based on acrylic acid, 2-ethylhexyl acrylate and vinyl acetate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and methyl acrylate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and methyl acrylate, based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate, vinyl acetate, 2-hydroxyethyl acrylate and methyl methacrylate, based on acrylic acid, butyl acrylate, 2-ethylhexyl
- the adhesive polyacrylate mentioned first based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate is preferably produced from a monomer mixture, which contains 1 to 10% by weight, preferably 3 to 7% by weight and especially preferably about 5% by weight acrylic acid, 5 to 25% by weight, preferably 10 to 20% by weight, and especially preferably about 15% by weight butyl acrylate, 60 to 80% by weight, preferably 70 to 78% by weight, and especially preferably about 75% by weight 2-ethylhexyl acrylate and 1 to 10% by weight, preferably 2 to 8% by weight, and especially preferably about 5% by weight vinyl acetate.
- the adhesive polyacrylate based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate are preferably produced from a monomer mixture, which contains 1 to 10% by weight, preferably 2 to 8% by weight, and especially preferably about 5.7% by weight acrylic acid, 50 to 70% by weight, preferably 55 to 65% by weight, and especially preferably about 62.2% by weight 2-ethylhexyl acrylate and 20 to 40% by weight, preferably 30 to 35% by weight, and especially preferably about 32% by weight methyl acrylate.
- glycidyl methacrylate for example less than 1% by weight, preferably less than 0.05% by weight, and especially preferably about 0.03% by weight, glycidyl methacrylate can also be present.
- the polymer matrix of the transdermal therapeutic system according to the invention contains more than 10% by weight and especially preferably more than 20% by weight 5-aminolevulinic acid hydrochloride. It was experimentally established that the release of the 5-aminolevulinic acid hydrochloride increases within the first hour, by increasing the active ingredient quantity from 20% by weight to 30% by weight, by about a factor of 6.
- the quantity of the polyacrylate used in the transdermal therapeutic system according to the invention is preferably more than 60% by weight and especially preferably more than 70% by weight.
- the transdermal therapeutic system is a monolithic active ingredient-in-adhesive system, more than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are smaller than 250 ⁇ m
- the adhesive polyacrylate is based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate and especially preferably on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate
- the polymer matrix contains 25 to 30% by weight, preferably about 28% by weight, 5-aminolevulinic acid hydrochloride and 70 or more % by weight, preferably about 72% by weight, polyacrylate.
- a system of this type exhibits a very rapid release of a large quantity of active ingredient and the processability is excellent.
- the transdermal therapeutic system according to the invention is produced in a known manner.
- An active ingredient-containing adhesive mass based on an adhesive polyacrylate is firstly produced.
- Ethanol, ethyl acetate, heptane, hexane, isopropyl alcohol, methanol, toluene, 2,4-pentandiene and mixtures thereof are preferably possible solvents.
- Ethyl acetate and hexane are especially preferred.
- Conventional coating, drying and laminating methods and cutting follow. The solvent is almost completely removed during the drying process. Perforation and packaging finally follow.
- the present invention also relates to the use of the transdermal therapeutic system according to the invention for the diagnosis and therapy of preliminary skin cancer stages, such as actinic keratosis, and of skin cancer and oncological skin diseases.
- the external application of the transdermal therapeutic system leads to the penetration and enrichment of the active ingredient in the diseased tissue.
- 5-aminolevulinic acid hydrochloride is an endogenous compound and a precursor substance in the biosynthesis of porphyrins, which are constituents, for example, of the haemoglobin and the cytochrome cycle. 5-aminolevulinic acid hydrochloride is converted into the actual photosensitiser, the protoporphyrin IX (PPlX).
- an irradiation takes place with adequate light, for example with light of various wavelengths, such as, for example, 408 mm, 506 mm, 532 mm, 580 mm and 635 mm.
- light of various wavelengths such as, for example, 408 mm, 506 mm, 532 mm, 580 mm and 635 mm.
- reactive oxygen compounds are produced, which make the target tissue visible during the diagnosis or lead to an apoptosis and necrosis thereof during the therapy.
- the present invention also relates to a transdermal therapeutic system, as described above, as a therapeutic agent.
- the present invention relates to a transdermal therapeutic system, as described above, for treating preliminary skin cancer stages, such as, for example, actinic keratosis, and oncological skin diseases.
- the transdermal therapeutic system is preferably used to treat actinic keratosis.
- the transdermal therapeutic system produced contains the following constituents:
- composition of this example corresponds to Example 1, except that instead of DURO-TAK 387-2353, the same quantity of DURO-TAK 387-2052 (polyacrylate with cross-linking agent) was used.
- composition of this example corresponds to Example 1, except that instead of DURO-TAK 387-2353, the same quantity of Bio-PSA 4301 (a silicone polymer) was used.
- FIG. 1 is a graph showing released quantity 5-ALA [mg/patch] versus time [h] for Examples 1, 2, and 3.
- Example 1 is acrylate (non cross-linked)
- Example 2 is acrylate (cross-linked)
- Example 3 is silicone (comparative).
- the release rate of a transdermal therapeutic system according to Example 1 is higher than that according to Example 2. Both Example 1 and Example 2 exhibit a clearly faster release compared to comparative Example 3. Furthermore, the stability of the 5-aminolevulinic acid hydrochloride according to Example 1 after one and three months is higher than that of the 5-aminolevulinic acid hydrochloride according to Example 2, which is degraded more quickly.
Abstract
Description
- This continuation application claims priority to U.S. patent application Ser. No. 14/240,810, filed Jun. 18, 2014 (allowed), which claims priority to PCT/EP2012/066541, filed Aug. 24, 2012, which further claims priority to its parent application, German Patent Application No. DE 10 2011 111 865.2, filed Aug. 31, 2011. U.S. patent application Ser. No. 14/240,810, International Application No. PCT/EP2012/066541, and German Patent Application No. DE 10 2011 111 865.2 are each hereby incorporated herein by reference in their entirety.
- The present invention relates to a transdermal therapeutic system and a transdermal active ingredient-containing plaster for 5-aminolevulinic acid hydrochloride. It also relates to the use of a system of this type in photodynamic diagnostics and therapy.
- It is noted that citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.
- Transdermal therapeutic systems have become widespread nowadays as a form of administration for treating numerous diseases, as they demonstrate certain advantages compared to conventional forms of administration. Thus, transdermal therapeutic systems can increase the therapeutic value of an active ingredient as they ensure a constant dispensing thereof. The advantages of transdermal therapeutic systems are also that, in comparison to ointments or creams, they can be applied to the precise area and therefore at the precise dosage. Furthermore, there is no danger of inadvertently wiping off the ointment and contaminating other locations on the skin.
- A transdermal therapeutic system for releasing 5-aminolevulinic acid is known from
EP 1 467 706 A1. 5-aminolevulinic acid is selectively absorbed and enriched by tumor tissue, so it only leads to an increased porphyrin formation and concentration there, while the healthy tissue remains substantially uninfluenced. The effect of the 5-aminolevulinic acid is based on the stimulation of the body's own porphyrin formation. As the porphyrin strongly fluoresces upon irradiation, the 5-aminolevulinic acid or porphyrin enrichment can be used in diseased tissue to diagnose precancerous and cancerous lesions and for the protodynamic therapy thereof. A similar system is also known fromEP 1 303 267 A1. The two systems have the drawback that the 5-aminolevulinic acid permeates through human skin only comparatively poorly. - Actinic keratosis is designated an early form of white skin cancer, as the latter in 10% of cases can develop within a period of 10 years into a squamous cell carcinoma of the skin (spinalioma). It is chronic damage to the horny epidermis caused by the intensive action of sunlight (UV radiation) over many years. An important treatment method for actinic keratosis is so-called photodynamic therapy. An active ingredient is firstly applied here to the affected skin region and specific light-sensitive substances, the so-called porphyrins, increasingly form in the diseased skin cells. As a result, the cells are sensitised to the subsequent treatment with light and reactive oxygen is produced (photodynamic effect), which ultimately leads to the death of the corresponding cells. Good cosmetic results can generally be achieved using the photodynamic therapy. The photodynamic therapy can furthermore be repeated virtually as often as desired if the actinic keratosis occurs again. Apart from the therapeutic effect, photodynamic therapy also offers a diagnostic use. Using special light, the regions affected by actinic keratosis and pretreated by corresponding substances can be made visible in a targeted manner. It is thus possible to recognise the actinic keratosis early and to precisely determine the size of the locations affected (photodynamic diagnostics).
- It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. patent law; e.g. they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of” and “consists essentially of” have the meaning ascribed to them in U.S. patent law, e.g. they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention. Applicants further reserve the right to disclaim, and hereby disclose a disclaimer of, any previously described product, method of making the product, or process of using the product.
- The aim of the present invention is to provide a transdermal therapeutic system, which as quickly as possible releases an adequate quantity of a substance into precancerous and cancerous lesions in order to then carry out the photodynamic therapy by means of irradiation. The transdermal therapeutic system should be well tolerated by the skin, be flexible and adequately sticky, even on regions that are less well accessible, such as the nasal bone or the outer ear. Furthermore, the transdermal therapeutic system should be stable, visually unobtrusive, easy to apply and remove again.
- The above aim is addressed by a transdermal therapeutic system or a transdermal active ingredient-containing plaster, which comprises a back layer that is impermeable to an active ingredient, an active ingredient-containing polymer matrix and a protective layer that can be pulled off, and characterised in that 5-aminolevulinic acid hydrochloride is used as the active ingredient and in that the basic polymer of the polymer matrix is an adhesive polyacrylate.
-
FIG. 1 graphically illustrates the released quantity of 5-ALA [mg/patch] versus time [h] for several exemplary embodiments. - It is to be understood that the figures and descriptions of the present invention have been simplified to illustrate elements that are relevant for a clear understanding of the present invention, while potentially eliminating, for purposes of clarity, many other elements which are conventional in this art. Those of ordinary skill in the art will recognize that other elements may be desirable for implementing the present invention. However, because such elements are well known in the art, and because they do not facilitate a better understanding of the present invention, a discussion of such elements is not provided herein.
- The present invention will now be described in detail on the basis of exemplary embodiments.
- The transdermal therapeutic system according to the invention with 5-aminolevulinic acid hydrochloride as the active ingredient and an adhesive polyacrylate as the basic polymer of the polymer matrix is in a position to absorb adequately large quantities of the suspended pharmaceutical agent, i.e. of the 5-aminolevulinic acid hydrochloride. There is good compatibility between the adhesive polyacrylate used and the 5-aminolevulinic acid hydrochloride. The release rate of the 5-aminolevulinic acid hydrochloride during the application period is extraordinarily high. Furthermore, the transdermal therapeutic system according to the invention adheres adequately to the skin but does not irritate it The transdermal therapeutic system according to the invention can easily be applied, especially also to small skin regions, such as the forehead, the outer ear or the nose.
- According to a preferred embodiment, the transdermal therapeutic system according to the invention is characterised in that it is capable, within about four hours, preferably within about an hour and especially preferably within about thirty minutes, of releasing a quantity of at least 3 mg 5-aminolevulinic acid hydrochloride (measured as 5-aminolevulinic acid with the so-called “paddle over disc” method, as described in European Pharmacopoeia 6.0, 2.9A “dissolution test for transdermal patches”, January 2008: 20904; see also Example 4).
- The transdermal therapeutic system according to the invention is preferably a monolithic active ingredient-in-adhesive system (monolithic drug-in-adhesive system). 5-aminolevulinic acid hydrochloride is suspended or dispersed directly in the polymer matrix here. The polymer matrix carries out the three functions of the active ingredient reservoir, the control element and the adhesive layer in this case. A system of this type consists only of a back layer that is impermeable to an active ingredient, an active ingredient-containing polymer matrix and a protective layer that can be pulled off. The polymer matrix influences the adhesion to the skin, the storage of the 5-aminolevulinic acid hydrochloride and its release. A system of this type leads to a plurality of advantages during the release of hydrophilic substances, such as 5-aminolevulinic acid hydrochloride. Thus, further hydrophilic matrix materials can be avoided, so the microbiological stability is improved. The stability of the active ingredient is also increased as it is chemically inactivated. It is furthermore possible to control the release of the active ingredient by means of the particle size.
- The back layer that is impermeable to the active ingredient is preferably inert and as flexible as possible, so the transdermal therapeutic system can also be applied to irregular skin regions. Any suitable material, such as, for example, polyethylene terephthalate, polyethylene, polybutylene, polyurethane, polyester, etc., can be used for the back layer. The back layer that is impermeable to an active ingredient is preferably an optionally aluminised polyester film, especially preferably a laminate made of pigmented polyethylene with aluminium vapour-coated polyester, which (provide) protection against light irradiation and therefore prevent photosensitisation before the actual photodynamic therapy.
- The protective layer that can be pulled off can be produced from various materials, such as, for example, polyethylene terephthalate, polyethylene or polypropylene and is specially treated on the side in contact with the active ingredient-containing polymer matrix in order to make it as easy as possible to remove therefrom. The protective layer that can be pulled off is advantageously based on a polyethylene terephthalate layer.
- In a preferred embodiment, the active ingredient 5-aminolevulinic acid hydrochloride is present as a crystalline 5-aminolevulinic acid hydrochloride. This has the advantage that the solubility of the active ingredient in the matrix does not have to be adjusted. Furthermore, an over-saturation and a constant diffusion pressure are thereby achieved.
- In a preferred embodiment, about 50% of the crystals or particles of the crystalline 5-aminolevulinic acid hydrochloride are greater than the layer thickness of the polymer matrix. The active ingredient projects, so to speak, from the matrix, which has the advantage that on contact with the skin, especially with sweat, the projecting crystals very quickly dissolve and can therefore be easily and quickly transdermally absorbed.
- More than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are preferably smaller than about 250 μm. Although as the crystal size becomes larger, the epidermal flow increases, crystals that are too large, i.e. crystal sizes above about 250 μm, lead to clumping and streak formation.
- On the other hand, it is preferred for the quantity of crystals, which are smaller than 90 μm, to make up at most 50%, and the quantity of crystals, which are smaller than 50 μm, to make up at most 25%, of the active ingredient mass, as this ensures a high active ingredient flow.
- A transdermal therapeutic system with 5-aminolevulinic acid hydrochloride crystals of a particle size of 90 to 160 μm exhibits a clearly improved transepidermal flow compared with a system with particles having a particle size of less than 90 μm. This is probably because more active ingredient is released and is therefore available for the permeation. Particle sizes in the range from 90 to 160 μm are therefore especially preferred.
- The polymer matrix of the transdermal therapeutic system according to the invention preferably contains less than 30% by weight, preferably less than 20% by weight and especially preferably less than 5% by weight of plasticiser, for example citric acid esters, such as acetyl tributyl citrate, in relation to polyacrylate. The plasticiser content in the transdermal therapeutic system according to the invention is quite especially preferably below 5000 ppm.
- So-called enhancers or permeation promoters can also preferably be dispensed with.
- The adhesive polyacrylate can be obtained with and advantageously without cross-linking agents (cross-linkers), such as, for example, aluminium acetylacetonate, polybutyl titanate or t-amyl peroxy pyrolate, etc.
- The adhesive polyacrylate preferably has acid functionalities (carboxyl groups), as they are advantageous in relation to the adhesion. These are especially important when the crystals of the crystalline 5-aminolevulinic acid hydrochloride are larger than the layer thickness of the polymer matrix as whole-area contact between the transdermal therapeutic system and the skin is not then ensured. The adhesive polyacrylate with acid functionalities can, for example, be obtained by polymerisation of a monomer mixture containing an unsaturated carboxylic acid, such as, for example, acrylic acid, methacrylic acid or maleic acid.
- The monomer mixtures used to produce the adhesive polyacrylates can also contain acrylic acid derivatives with epoxy groups, such as, for example, glycidyl (meth)acrylate.
- The polyacrylate is preferably based on acrylic esters, such as, for example, 2-ethylhexyl acrylate. This is preferably used in a quantity of more than 50% by weight, especially more than 60% by weight and especially preferably in a quantity of more than 70% by weight, based on polyacrylate.
- The viscosity of the polyacrylate is preferably in the range from 500 to 25,000, especially preferably in the range from 1,000 to 20,000 and quite especially preferably in the range from 1,500 to 12,000 mPa·s at 25° C.
- In a preferred embodiment, the adhesive polyacrylate is polyacrylate based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and vinyl acetate, based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate, based on acrylic acid, 2-ethylhexyl acrylate and vinyl acetate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and methyl acrylate, based on 2-ethylhexyl acrylate, 2-hydroxyethyl acrylate and methyl acrylate, based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate, vinyl acetate, 2-hydroxyethyl acrylate and methyl methacrylate, based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate, vinyl acetate, t-octylacrylamide and vinyl acetate and based on 2-ethylhexyl acrylate and vinyl acetate.
- Adhesive acrylates based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate and adhesive polyacrylates based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate, the latter supplying the best results, are especially preferred.
- The adhesive polyacrylate mentioned first based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate is preferably produced from a monomer mixture, which contains 1 to 10% by weight, preferably 3 to 7% by weight and especially preferably about 5% by weight acrylic acid, 5 to 25% by weight, preferably 10 to 20% by weight, and especially preferably about 15% by weight butyl acrylate, 60 to 80% by weight, preferably 70 to 78% by weight, and especially preferably about 75% by weight 2-ethylhexyl acrylate and 1 to 10% by weight, preferably 2 to 8% by weight, and especially preferably about 5% by weight vinyl acetate.
- The adhesive polyacrylate based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate are preferably produced from a monomer mixture, which contains 1 to 10% by weight, preferably 2 to 8% by weight, and especially preferably about 5.7% by weight acrylic acid, 50 to 70% by weight, preferably 55 to 65% by weight, and especially preferably about 62.2% by weight 2-ethylhexyl acrylate and 20 to 40% by weight, preferably 30 to 35% by weight, and especially preferably about 32% by weight methyl acrylate. In the case of the latter, small quantities of glycidyl methacrylate, for example less than 1% by weight, preferably less than 0.05% by weight, and especially preferably about 0.03% by weight, glycidyl methacrylate can also be present.
- In a preferred embodiment, the polymer matrix of the transdermal therapeutic system according to the invention contains more than 10% by weight and especially preferably more than 20% by weight 5-aminolevulinic acid hydrochloride. It was experimentally established that the release of the 5-aminolevulinic acid hydrochloride increases within the first hour, by increasing the active ingredient quantity from 20% by weight to 30% by weight, by about a factor of 6.
- On the other hand quantities of 5-aminolevulinic acid hydrochloride that are too large lead to a deterioration in the ability to adhere to the skin and to problems in the coating. It is therefore preferred if less than 35% by weight and especially less than 30% by weight 5-aminolevulinic acid hydrochloride is present. The range between 25 and 30% by weight is optimal.
- The quantity of the polyacrylate used in the transdermal therapeutic system according to the invention is preferably more than 60% by weight and especially preferably more than 70% by weight.
- In a preferred embodiment, the transdermal therapeutic system is a monolithic active ingredient-in-adhesive system, more than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are smaller than 250 μm, the adhesive polyacrylate is based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate and especially preferably on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate, and the polymer matrix contains 25 to 30% by weight, preferably about 28% by weight, 5-aminolevulinic acid hydrochloride and 70 or more % by weight, preferably about 72% by weight, polyacrylate. A system of this type exhibits a very rapid release of a large quantity of active ingredient and the processability is excellent.
- The transdermal therapeutic system according to the invention is produced in a known manner. An active ingredient-containing adhesive mass based on an adhesive polyacrylate is firstly produced. Ethanol, ethyl acetate, heptane, hexane, isopropyl alcohol, methanol, toluene, 2,4-pentandiene and mixtures thereof are preferably possible solvents. Ethyl acetate and hexane are especially preferred. Conventional coating, drying and laminating methods and cutting follow. The solvent is almost completely removed during the drying process. Perforation and packaging finally follow.
- The present invention also relates to the use of the transdermal therapeutic system according to the invention for the diagnosis and therapy of preliminary skin cancer stages, such as actinic keratosis, and of skin cancer and oncological skin diseases. The external application of the transdermal therapeutic system leads to the penetration and enrichment of the active ingredient in the diseased tissue. 5-aminolevulinic acid hydrochloride is an endogenous compound and a precursor substance in the biosynthesis of porphyrins, which are constituents, for example, of the haemoglobin and the cytochrome cycle. 5-aminolevulinic acid hydrochloride is converted into the actual photosensitiser, the protoporphyrin IX (PPlX). After the enrichment, an irradiation takes place with adequate light, for example with light of various wavelengths, such as, for example, 408 mm, 506 mm, 532 mm, 580 mm and 635 mm. In this case, reactive oxygen compounds are produced, which make the target tissue visible during the diagnosis or lead to an apoptosis and necrosis thereof during the therapy.
- The present invention also relates to a transdermal therapeutic system, as described above, as a therapeutic agent.
- Furthermore, the present invention relates to a transdermal therapeutic system, as described above, for treating preliminary skin cancer stages, such as, for example, actinic keratosis, and oncological skin diseases. The transdermal therapeutic system is preferably used to treat actinic keratosis.
- The subject matter of the present invention is elucidated in more detail below, using examples and a figure, without any intention that the subject matter of the invention should be confined to these exemplary embodiments or figure.
- The transdermal therapeutic system produced contains the following constituents:
-
% (% by weight/ % by weight) mg/Plaster Active ingredient: 5-aminolevulinic 19.7 10.2 acid hydrochloride Polymera): DURO-TAK 49.6 25.8 387-2353 Back layer: 3M SCOTCHPAK ™ 30.7 16.0 1109 Protective layer: polyethylene b) 59.0c) terephthalate layer siliconised on one side (75 μm) a)in ethyl acetate and hexane, which are both virtually completely removed during the drying process b)is removed before application c)estimated - In relation to the polymer matrix, 28% by weight 5-aminolevulinic acid hydrochloride and 72% by weight DURO-TAK 387-2353 (polyacrylate without cross-linking agent) are accordingly present.
- The composition of this example corresponds to Example 1, except that instead of DURO-TAK 387-2353, the same quantity of DURO-TAK 387-2052 (polyacrylate with cross-linking agent) was used.
- The composition of this example corresponds to Example 1, except that instead of DURO-TAK 387-2353, the same quantity of Bio-PSA 4301 (a silicone polymer) was used.
- The release rate was measured using the so-called “paddle over disc” method, as described in European Pharmacopoeia 6.0, 2.9.4. “dissolution test for transdermal patches”, January 2008: 20904, under the following conditions:
- Apparatus used: paddle over disc
Release medium: citrate buffer pH 3.0
Volume of the release medium: 300 ml - Rotation frequency: 50 min−1
Sample removal time: 0.5 h, 2 h and 7 h
Sample volume: 10.0 ml - The results are shown in
FIG. 1 . Specifically,FIG. 1 is a graph showing released quantity 5-ALA [mg/patch] versus time [h] for Examples 1, 2, and 3. Example 1 is acrylate (non cross-linked), Example 2 is acrylate (cross-linked), and Example 3 is silicone (comparative). - The release rate of a transdermal therapeutic system according to Example 1 is higher than that according to Example 2. Both Example 1 and Example 2 exhibit a clearly faster release compared to comparative Example 3. Furthermore, the stability of the 5-aminolevulinic acid hydrochloride according to Example 1 after one and three months is higher than that of the 5-aminolevulinic acid hydrochloride according to Example 2, which is degraded more quickly.
- While this invention has been described in conjunction with the specific embodiments outlined above, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, the preferred embodiments of the invention as set forth above are intended to be illustrative, but not limiting. Various changes may be made without departing from the spirit and scope of the inventions as defined in the following claims.
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/388,364 US20190240166A1 (en) | 2011-08-31 | 2019-04-18 | Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011111865.2 | 2011-08-31 | ||
DE102011111865A DE102011111865A1 (en) | 2011-08-31 | 2011-08-31 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
PCT/EP2012/066541 WO2013030129A1 (en) | 2011-08-31 | 2012-08-24 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
US201414240810A | 2014-06-18 | 2014-06-18 | |
US16/388,364 US20190240166A1 (en) | 2011-08-31 | 2019-04-18 | Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/066541 Continuation WO2013030129A1 (en) | 2011-08-31 | 2012-08-24 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
US14/240,810 Continuation US10307382B2 (en) | 2011-08-31 | 2012-08-24 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190240166A1 true US20190240166A1 (en) | 2019-08-08 |
Family
ID=46724447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/240,810 Active 2034-05-07 US10307382B2 (en) | 2011-08-31 | 2012-08-24 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
US16/388,364 Abandoned US20190240166A1 (en) | 2011-08-31 | 2019-04-18 | Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/240,810 Active 2034-05-07 US10307382B2 (en) | 2011-08-31 | 2012-08-24 | Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
Country Status (17)
Country | Link |
---|---|
US (2) | US10307382B2 (en) |
EP (1) | EP2750673B1 (en) |
JP (2) | JP6035335B2 (en) |
KR (1) | KR101933610B1 (en) |
CN (1) | CN103764135B (en) |
AU (1) | AU2012301042B2 (en) |
BR (1) | BR112014004635B1 (en) |
CA (1) | CA2844288C (en) |
DE (1) | DE102011111865A1 (en) |
DK (1) | DK2750673T3 (en) |
ES (1) | ES2646737T3 (en) |
MX (1) | MX351514B (en) |
NO (1) | NO2750673T3 (en) |
PL (1) | PL2750673T3 (en) |
PT (1) | PT2750673T (en) |
RU (1) | RU2607657C2 (en) |
WO (1) | WO2013030129A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116407B2 (en) | 2016-11-17 | 2021-09-14 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
US11250945B2 (en) | 2016-05-02 | 2022-02-15 | Aranz Healthcare Limited | Automatically assessing an anatomical surface feature and securely managing information related to the same |
US11850025B2 (en) | 2011-11-28 | 2023-12-26 | Aranz Healthcare Limited | Handheld skin measuring or monitoring device |
US11903723B2 (en) | 2017-04-04 | 2024-02-20 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ307444B6 (en) * | 2015-04-22 | 2018-08-29 | Jakub Rak | Mucoadhesive polymer film for photosensitive therapy in the oral cavity containing photosensitizers |
KR102171200B1 (en) | 2018-11-20 | 2020-10-28 | 제너럴바이오(주) | Composition for the treatment or improvement of Acne dermatitis comprising 5-aminolevulinic acid hydrochloride and its derivatives |
CN111517973B (en) * | 2019-02-02 | 2023-08-04 | 中国科学院天津工业生物技术研究所 | Production process for preparing 5-aminolevulinic acid hydrochloride from fermentation broth and application of production process |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006602A1 (en) | 1993-08-27 | 1996-03-07 | Noven Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF δ-AMINOLEVULINIC ACID AND PHARMACEUTICAL EQUIVALENTS THEREOF |
GR1002807B (en) | 1996-06-20 | 1997-11-13 | Lavipharm A.E. | Device for topical treatment of acne and method of manufacture. |
HU0200901D0 (en) * | 1996-06-20 | 2002-08-28 | Lavipharm Sa | |
US5856566A (en) * | 1997-09-02 | 1999-01-05 | Dusa Pharmaceuticals, Inc. | Sterilized 5-aminolevulinic acid |
ATE288256T1 (en) * | 1999-01-14 | 2005-02-15 | Noven Pharma | DERMAL COMPOSITIONS |
DE10034673C1 (en) * | 2000-07-17 | 2002-04-25 | Medac Klinische Spezialpraep | Dermal application system for aminolevulinic acid and its use |
DE60141758D1 (en) * | 2000-08-16 | 2010-05-20 | Gen Hospital Corp | Topische aminolevulinsäure-photodynamische therapie für akne vulgaris |
KR100846912B1 (en) | 2001-01-12 | 2008-07-17 | 페데랄노에고수다르스트벤노에유니타르노에프레드프리야티에고수다르스트벤니나우쉬니티센트르나우쉬노이슬레도바텔스키인스티튜트오르가니쉐스키크흐포루프로두크토브아이크르아시텔에이에프지업지엔트스니오피크 | Method for photodynamic therapy and applicator for carrying out said therapy |
ATE419897T1 (en) * | 2001-10-24 | 2009-01-15 | Power Paper Ltd | DEVICE FOR THE CONTROLLED DELIVERY OF AN ACTIVE SUBSTANCE INTO THE SKIN |
DE10200578A1 (en) | 2002-01-09 | 2003-07-10 | Roehm Gmbh | Adhesive and binding agents for dermal or transdermal therapy systems |
DE10202487A1 (en) * | 2002-01-23 | 2003-07-31 | Photonamic Gmbh & Co Kg | Dermal application system for aminolevulinic acid derivatives |
DE10344334A1 (en) | 2003-09-24 | 2005-04-28 | Johann Berger | Woven webbing |
EP1847264B1 (en) | 2005-01-31 | 2017-05-03 | Hisamitsu Pharmaceutical Co., Inc. | Bisoprolol patch |
US20060182790A1 (en) * | 2005-02-17 | 2006-08-17 | Flor Mayoral | Dermal medicaments application enhancer |
US20100087768A1 (en) * | 2008-10-02 | 2010-04-08 | Forlano Paula | Transdermal drug delivery system for liquid active ingredient |
-
2011
- 2011-08-31 DE DE102011111865A patent/DE102011111865A1/en not_active Ceased
-
2012
- 2012-08-24 JP JP2014527607A patent/JP6035335B2/en active Active
- 2012-08-24 AU AU2012301042A patent/AU2012301042B2/en active Active
- 2012-08-24 CA CA2844288A patent/CA2844288C/en active Active
- 2012-08-24 RU RU2014111255A patent/RU2607657C2/en active
- 2012-08-24 ES ES12750597.2T patent/ES2646737T3/en active Active
- 2012-08-24 NO NO12750597A patent/NO2750673T3/no unknown
- 2012-08-24 WO PCT/EP2012/066541 patent/WO2013030129A1/en active Application Filing
- 2012-08-24 EP EP12750597.2A patent/EP2750673B1/en active Active
- 2012-08-24 CN CN201280041826.1A patent/CN103764135B/en active Active
- 2012-08-24 BR BR112014004635-2A patent/BR112014004635B1/en active IP Right Grant
- 2012-08-24 US US14/240,810 patent/US10307382B2/en active Active
- 2012-08-24 PL PL12750597T patent/PL2750673T3/en unknown
- 2012-08-24 PT PT127505972T patent/PT2750673T/en unknown
- 2012-08-24 MX MX2014002215A patent/MX351514B/en active IP Right Grant
- 2012-08-24 DK DK12750597.2T patent/DK2750673T3/en active
- 2012-08-24 KR KR1020147008255A patent/KR101933610B1/en active IP Right Grant
-
2016
- 2016-10-28 JP JP2016211246A patent/JP6203364B2/en active Active
-
2019
- 2019-04-18 US US16/388,364 patent/US20190240166A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11850025B2 (en) | 2011-11-28 | 2023-12-26 | Aranz Healthcare Limited | Handheld skin measuring or monitoring device |
US11250945B2 (en) | 2016-05-02 | 2022-02-15 | Aranz Healthcare Limited | Automatically assessing an anatomical surface feature and securely managing information related to the same |
US11923073B2 (en) | 2016-05-02 | 2024-03-05 | Aranz Healthcare Limited | Automatically assessing an anatomical surface feature and securely managing information related to the same |
US11116407B2 (en) | 2016-11-17 | 2021-09-14 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
US11903723B2 (en) | 2017-04-04 | 2024-02-20 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
Also Published As
Publication number | Publication date |
---|---|
EP2750673B1 (en) | 2017-08-09 |
EP2750673A1 (en) | 2014-07-09 |
JP6035335B2 (en) | 2016-11-30 |
PL2750673T3 (en) | 2018-11-30 |
JP6203364B2 (en) | 2017-09-27 |
DE102011111865A1 (en) | 2013-02-28 |
CA2844288A1 (en) | 2013-03-07 |
BR112014004635A2 (en) | 2017-03-14 |
DK2750673T3 (en) | 2017-11-20 |
KR20140056370A (en) | 2014-05-09 |
ES2646737T3 (en) | 2017-12-15 |
MX351514B (en) | 2017-10-17 |
US20140323994A1 (en) | 2014-10-30 |
NO2750673T3 (en) | 2018-01-06 |
JP2017061489A (en) | 2017-03-30 |
KR101933610B1 (en) | 2018-12-28 |
US10307382B2 (en) | 2019-06-04 |
RU2607657C2 (en) | 2017-01-10 |
WO2013030129A1 (en) | 2013-03-07 |
BR112014004635B1 (en) | 2022-09-13 |
AU2012301042A1 (en) | 2014-03-20 |
JP2014527537A (en) | 2014-10-16 |
PT2750673T (en) | 2017-11-15 |
CN103764135B (en) | 2018-06-22 |
AU2012301042B2 (en) | 2017-07-13 |
CA2844288C (en) | 2019-08-20 |
RU2014111255A (en) | 2015-10-10 |
MX2014002215A (en) | 2014-04-30 |
CN103764135A (en) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190240166A1 (en) | Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride | |
KR101444967B1 (en) | Transdermal therapeutic system for administering the active substance buprenorphine | |
EP0464573B1 (en) | Plaster high in softening substances | |
EP1696013B1 (en) | Pressure sensitive adhesive and patch | |
JP5913981B2 (en) | Donepezil-containing transdermal preparation | |
HU222499B1 (en) | Controlled release pharmaceutical composition containing estradiol penetration intensifier agent for transdermal administration and process for its preparation | |
JP2011513287A (en) | Pharmaceutical composition | |
PT1467706E (en) | Dermal application system for aminolevulinic acid-derivatives | |
JP2004010525A (en) | Percutaneous absorption type preparation and method for producing the same | |
EA023786B1 (en) | Propynylaminoindan transdermal compositions | |
KR100473677B1 (en) | Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties | |
WO2008026381A1 (en) | Nail patch | |
JP4469131B2 (en) | Skin application system for aminolevulinic acid | |
RU2322234C2 (en) | Method for preventing and/or treating onychomycosis, adhesive bandage for its implementation and its application | |
JP4851671B2 (en) | Tranilast transdermal patch and method for producing the same | |
JPH01233213A (en) | Plaster and production thereof | |
JPH07116025B2 (en) | Patch | |
JP5389824B2 (en) | Transdermal therapeutic system having urea component | |
KR20130049353A (en) | Transdermal patch for administering fentanyl | |
JP3242324B2 (en) | Nitroglycerin transdermal preparation | |
KR20100117387A (en) | A new transdermal combination composition of dexibuprofen and tulobuterol | |
JPH11349477A (en) | Percutaneous absorptive patch | |
JP2005008612A (en) | Plaster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHOTONAMIC GMBH & CO. KG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LTS LOHMANN THERAPIE-SYSTEME AG;REEL/FRAME:049890/0391 Effective date: 20190321 Owner name: LTS LOHMANN THERAPIE-SYSTEME AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JUNG, TOBIAS;HORSTMANN, MICHAEL;HOFFMANN, GERD;SIGNING DATES FROM 20140312 TO 20140430;REEL/FRAME:049890/0236 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |